Oral suspension of thaliporphine alter the functional dyspepsia in gastroduodenal lesions rats via gastrointestinal hormones and brain-gut peptides

Abstract

Functional dyspepsia (FD), also known as nonulcer dyspepsia, is distinguished by epigastric burning or pain, nausea, a feeling of being overly full, and bloating. Thaliporphine an alkaloid exhibited the protective effect against the inflammatory reaction and oxidative stress. Our aim to scrutinized the therapeutic potential of thaliporphine against FD in rats. Sprague-Dawley (SD) rats were randomised into six groups at random, and the FD model was created using irregular tail clamp stimulation over 14 days (except from rats in the control group). The normal and model group rats got menstruum and thaliporphine oral administration for 14 days after the FD rat models were effectively established. The body weight, food and water intake were estimated. The level of plasma gastrin (GAS), motilin (MTL), vasoactive intestinal peptide (VIP), somatostatin (SS), calcitonin gene-related peptide (CGRP), acetylcholine (AChE), antioxidant, cytokines and inflammatory parameters were estimated. Thaliporphine treated group rats exhibited the increased body weight and food intake, which was suppressed during the FD. Thaliporphine significantly increased the rate of intestinal propulsion and gastric emptying in addition to changing the levels of leptin, CGRP, MLT, SS, and VIP. Thaliporphine significantly (P <0.001) reduced the level of AChE in serum and boosted the level in stomach and hypothalamus. Thaliporphine significantly changed the cytokine and inflammatory parameter levels. Treatment with thaliporphine improves gut peptide levels, controls the peripheral and central nervous systems, and restores levels of gastrointestinal hormones, all of which point to the drug’s potential for protecting against FD.